# A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

> **NCT05143177** · PHASE2,PHASE3 · SUSPENDED · sponsor: **REDNVIA Co., Ltd.** · enrollment: 580 (estimated)

## Conditions studied

- Calcific Aortic Valve Disease

## Interventions

- **DRUG:** Evogliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05143177
- **Lead sponsor:** REDNVIA Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-06-27
- **Primary completion:** 2026-05-15
- **Final completion:** 2026-12-30
- **Target enrollment:** 580 (ESTIMATED)
- **Why stopped:** The study is suspended due to sponsor's business decision. There were no safety issues influencing this course of action.
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143177, "A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05143177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*